ESR as a Preferred Marker for Polymyalgia Rheumatica

Diagnostic Value of ESR vs CRP in PMR

• The European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) recommend measuring both ESR and CRP as part of the basic laboratory dataset for PMR diagnosis and monitoring, with ESR being specifically mentioned as a key laboratory marker for long-term disease monitoring 1, 2
• ESR is associated with higher relapse rates and need for prolonged therapy in PMR patients, with high ESR (>40 mm/1st hour) being an independent risk factor for relapse 3, 1, 4

Clinical Application

• The EULAR/ACR guidelines suggest that ESR may be used to determine initial glucocorticoid dosing in PMR management algorithms, with high ESR (>40 mm/1st hour) being a factor that might favor higher initial doses 5, 6

Special Considerations

• PMR with normal inflammatory markers is considered an atypical presentation that warrants specialist referral according to current guidelines from the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) 3, 2

Management of Polymyalgia Rheumatica with Prednisolone

Understanding the Effect of Prednisolone on ESR

• The American College of Rheumatology and European League Against Rheumatism guidelines are not directly mentioned, but according to the Annals of the Rheumatic Diseases, corticosteroids suppress inflammatory markers including ESR, which can be low in a patient with polymyalgia rheumatica who is taking prednisolone 7

Clinical Implications for Diagnosis and Monitoring

• Clinical symptoms should guide management more than ESR values during the treatment phase, as stated in the context of the Annals of the Rheumatic Diseases 7

Practical Approach

• Base treatment adjustments primarily on clinical symptoms, such as pain, stiffness, and functional status, rather than ESR alone, as suggested by the Annals of the Rheumatic Diseases 7
• High baseline ESR before treatment predicts higher relapse risk and need for prolonged therapy, according to the Annals of the Rheumatic Diseases 8